Bio Plus Co

Bio Plus Co CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 325.19 %. In the previous year, CapEx to Operating Cash Flow Ratio was 433.59 % — a change of -25.00% (lower).

CapEx/OCF

325.19 %

YoY

-25.00%

Last updated:

CapEx to Operating Cash Flow Ratio of Bio Plus Co is 2025 325.19 % . CapEx to Operating Cash Flow Ratio of Bio Plus Co was 2024 433.59 % . It decreases by -25.00% lower compared to the previous year.

The Bio Plus Co CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
23.36 KRW
Jan 1, 2019
131.25 KRW
Jan 1, 2020
10.91 KRW
Jan 1, 2021
115.02 KRW
Jan 1, 2022
50.11 KRW
Jan 1, 2023
134.49 KRW
Jan 1, 2024
433.59 KRW
Jan 1, 2025
325.19 KRW
The Bio Plus Co CapEx/OCF history
YEARCapEx/OCFYoY
325.19 %-25.00%
433.59 %+222.40%
134.49 %+168.39%
50.11 %-56.43%
115.02 %+954.19%
10.91 %-91.69%
131.25 %+461.80%
23.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

CapEx to Operating Cash Flow Ratio of Bio Plus Co is 325.19 % in 2025.

CapEx to Operating Cash Flow Ratio of Bio Plus Co changed from 433.59 % to 325.19 %, representing a -25.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bio Plus Co

All Key Metrics — Bio Plus Co